A Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National University Hospital, Singapore
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01228045
First received: October 21, 2010
Last updated: January 13, 2014
Last verified: January 2014

October 21, 2010
January 13, 2014
February 2011
December 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01228045 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Not Provided

The investigators hypothesis is that the combination of TS-ONE with cisplatin and trastuzumab is safe and as effective as combination treatment for HER2 positive gastric cancer.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
Gastric Cancer
Drug: Trastuzumab in Combination with TS-ONE and cisplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
Not Provided
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with histologically proved adenocarcinoma of advanced gastric cancer.
  2. Patients who have HER2-positive cancer confirmed with IHC and/or FISH.
  3. Patients with proved presence of measurable (RECIST criteria) lesions within 28 days before enrollment.
  4. Patients without prior treatment (ex. radiotherapy, chemotherapy, hormonal therapy): Patients who completed adjuvant chemotherapy more than 180 days before may be enrolled but those who received TS-ONE or cisplatin shall be excluded.
  5. Patients with the following function of bone marrow, liver and kidney based on the laboratory tests measured within 14 days before enrollment. Hemoglobin >= 8.0 g/dL leukocytes >=3,000/mcL absolute neutrophil count >=1,500/mcL platelets >=100,000/mcL total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT)=<2.5 X institutional upper limit of normal ALP < twice of the upper limit of normal, creatinine within normal institutional limits or creatinine clearance >=60 mL/min for patients with creatinine levels above institutional normal (When AST(GOT), ALT(GPT) and ALP do not satisfy the conditions above and these values are considered to be caused by cancer, the decision is based on the discretion of investigators or co-investigators) Creatinine clearance can be estimated using Cockcroft-Gault formula man: Ccr (mL/min) = body weight (kg) x (140 - age)/(72 x serum creatinine (mg/dL)), woman: Ccr = male Ccr x 0.85].
  6. ECOG performance status =<2 (Karnofsky >60%; see Appendix A).
  7. Patients who are expected to survive more than 3 months after enrollment.
  8. Age >= 21.
  9. Patients of adequate oral intake.
  10. Patients who underwent electrocardiography within 28 days before enrollment.\
  11. Patients who give written informed consent for additional endoscopy to obtain fresh frozen tissue biopsies for translational studies at 2 time points pre-1st cycle of chemotherapy and at progression.
  12. Patients who give written informed consent for enrollment into trial.

Exclusion Criteria:

  1. Patients for whom TS-ONE or cisplatin or trastuzumab is contraindicated.
  2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TS-ONE, cisplatin and trastuzumab.
  3. Patients receiving any other investigational agents.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  5. Baseline heart function LVEF (Left Ventricular Ejection Fraction) < 50%.
  6. Patients with serious (ex. inpatient care is needed) complications (ex. intestinal paralysis, intestinal occlusion, interstitial pneumonia or pulmonary fibrosis, poorly-controlled diabetes, renal failure or hepatic cirrhosis).
  7. Patients with massive ascites (moderate or higher, beyond the pelvic cavity and retention on the anterior surface of the liver on CT) or pleural effusion retention.
  8. Patients with extensive bone metastasis.
  9. Patients with known brain metastases.
  10. Patients with fresh bleeding from the digestive tract which needs repeated blood transfusion.
  11. Patients with diarrhea (4 or more times per day or watery diarrhea).
  12. Patients with simultaneously active multiple cancer.
  13. Pregnant or lactating female.
  14. Patients with reproductive potential who refuse to use an adequate means of contraception (including male patients).
  15. Other patients evaluated to be inadequate to participate in the study by co-investigators.
  16. No informed consent for either treatment regimen or collection of fresh frozen biopsy tissue for translational studies.
Both
21 Years and older
No
Contact: Wei Peng Yong, MRCP, MB ChB 65 6772 4670 Wei_Peng_Yong@nuhs.edu.sg
Singapore
 
NCT01228045
S1/CDDP/Her
No
Not Provided
National University Hospital, Singapore
Not Provided
Not Provided
National University Hospital, Singapore
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP